SECOND AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • March 30th, 2022 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Second Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Amended and Restated Incentive Compensation Agreement, dated as of March 29, 2021, between the Company and the Executive.
INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • March 30th, 2022 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances • Maine
This INCENTIVE COMPENSATION AGREEMENT, dated as of March 28, 2022, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and MICHAEL F. BRIGHAM (the “Executive”).
SECOND AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • March 30th, 2022 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Second Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Amended and Restated Incentive Compensation Agreement, dated as of March 21, 2019, between the Company and the Executive.
AMENDED AND RESTATED SEPARATION AND DEFERRED COMPENSATION AGREEMENTSeparation and Deferred Compensation Agreement • March 30th, 2022 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Amended and Restated Separation and Deferred Compensation Agreement, dated as of March 28, 2022, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and MICHAEL F. BRIGHAM (the Executive”), and replaces and supersedes in its entirety the Severance Agreement, dated as of March 25, 2020, between the Company and the Executive.
